temic embolism based on blinded event assessment and intention-to-treat. Results: During 4268 patient-years (mean 18 months), 96 primary events occurred. The mean INR in the warfarin group (2.5±0.7) was within target range for 67% of follow-up. The primary event rate was 2.27%/year with warfarin and 2.23%/year with ximelagatran, relative risk reduction (RRR) 2% (95% CI -46%, 34%; p = NS). 66% of patients in the warfarin arm and 69% in the ximelagatran arm completed the trial on assigned treatment. On-treatment event rates were 2.09%/year and 1.82%/year in the warfarin and ximelagatran arms, respectively, RRR 13% (95% CI -38%, 45%; p = NS). Rates of disabling or fatal stroke, mortality, and major bleeding were similar in both groups. Combined minor and major hemorrhages were lower with ximelagatran than warfarin (40.0%/year vs 45.0%/year; RRR 11%, 95% CI 2%, 18%; p = 0.014). Within the first 6 months, serum alanine aminotransferase levels rose >3 times the upper limit of normal in 29 patients on warfarin (0.8%) vs 224 patients on ximelagatran (6.1%), but returned towards normal in all cases. Conclusion: In elderly, high-risk patients with AF, oral ximelagatran without coagulation monitoring or dose adjustment was at least as effective for prevention of stroke and systemic embolism, and associated with less bleeding than well-controlled warfarin. Background: Nonvalvular atrial fibrillation (AF) affects women less often than men, but the risk of stroke is greater among women. Warfarin protects against stroke, but is associated with bleeding, which occurs more often in women than in men. The oral direct thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alternative anticoagulant to warfarin. Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) noninferiority trials included 2257 women with AF and at least 1 stroke risk factor randomized to adjusted-dose warfarin (target INR 2.0-3.0) or fixed-dose ximelagatran (36 mg twice daily). The mean age of female participants (73.4±8.0 years) was similar to that of the 5072 males (69.9±9.1 years). The primary endpoint was stroke (ischemic or hemorrhagic) and systemic embolism based on blinded assessment and intention-to-treat. Results: During 11,233 patient-years (mean 19 months) exposure (3468 in women and 7765 in men) 72 primary events occurred in women and 112 in men. The mean INR with warfarin (2.5±0.7) was within target range for 67% of follow-up for both genders. In women, the primary event rate was 2.0%/year with warfarin and 2.2%/year with ximelagatran, relative risk reduction (RRR) -10% (95% CI -73%, 31%; p = NS); rates in men were 1.5%/year and 1.4%/year (RRR 9.0%, 95% CI -32%, 37%; p = NS). On-treatment event rates were 1.8%/year and 1.5%/year among women in the warfarin and ximelagatran groups (RRR 16%, 95% CI -46%, 52%; p = NS) compared with 1.5%/year and 1.4%/ year among men (RRR 5%, 95% CI -40%, 36%; p = NS). Combined rates of minor and major hemorrhages were greater among women (42.6%/year vs 36.9%/year on warfarin and 33.8%/year vs 30.8%/year on ximelagatran; treatment difference in women: p<0.0001). Within the first 6 months, serum alanine aminotransferase levels rose >3 times the upper limit of normal in 29 patients on warfarin (0.8%) vs 224 patients on ximelagatran (6.1%), but returned towards normal in all cases. Conclusion: In both women and men with AF, oral ximelagatran without coagulation monitoring or dose-adjustment was at least as effective as well-controlled warfarin for prevention of thromboembolism, and was associated with less bleeding.
Background: Nonvalvular atrial fibrillation (AF) affects women less often than men, but the risk of stroke is greater among women. Warfarin protects against stroke, but is associated with bleeding, which occurs more often in women than in men. The oral direct thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alternative anticoagulant to warfarin. Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) noninferiority trials included 2257 women with AF and at least 1 stroke risk factor randomized to adjusted-dose warfarin (target INR 2.0-3.0) or fixed-dose ximelagatran (36 mg twice daily). The mean age of female participants (73.4±8.0 years) was similar to that of the 5072 males (69.9±9.1 years). The primary endpoint was stroke (ischemic or hemorrhagic) and systemic embolism based on blinded assessment and intention-to-treat. Results: During 11,233 patient-years (mean 19 months) exposure (3468 in women and 7765 in men) 72 primary events occurred in women and 112 in men. The mean INR with warfarin (2.5±0.7) was within target range for 67% of follow-up for both genders. In women, the primary event rate was 2.0%/year with warfarin and 2.2%/year with ximelagatran, relative risk reduction (RRR) -10% (95% CI -73%, 31%; p = NS); rates in men were 1.5%/year and 1.4%/year (RRR 9.0%, 95% CI -32%, 37%; p = NS). On-treatment event rates were 1.8%/year and 1.5%/year among women in the warfarin and ximelagatran groups (RRR 16%, 95% CI -46%, 52%; p = NS) compared with 1.5%/year and 1.4%/ year among men (RRR 5%, 95% CI -40%, 36%; p = NS). Combined rates of minor and major hemorrhages were greater among women (42.6%/year vs 36.9%/year on warfarin and 33.8%/year vs 30.8%/year on ximelagatran; treatment difference in women: p<0.0001). Within the first 6 months, serum alanine aminotransferase levels rose >3 times the upper limit of normal in 29 patients on warfarin (0.8%) vs 224 patients on ximelagatran (6.1%), but returned towards normal in all cases. Conclusion: In both women and men with AF, oral ximelagatran without coagulation monitoring or dose-adjustment was at least as effective as well-controlled warfarin for prevention of thromboembolism, and was associated with less bleeding. Subjects were randomized to fosinopril 20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-300mg/24h) and no hypertension (<160/ 100mmHg). UAE was measured in 2x24 hour urine collection. UAE was dichotomized (low: first 4 quintiles, UAE < 50 mg/24h, high: upper quintiles, UAE > 50mg/24h). Results Mean age was 51.3 ± 11.8 years, 65% was male, mean cholesterol was 223 mg/ dl, mean systolic blood pressure was 130 mmHg and mean diastolic blood pressure was 76 mmHg. During a mean follow-up period of 46.2 ± 7.0 months, 42 (4.9%) cardiovascular events occurred. The figure below shows the Cox regression analysis divided by UAE and treatment. In the subjects with low UAE (group A), fosinopril reduced the events from 4.8 % to 3.0 % (relative risk reduction 37.5%). In the subjects with high UAE (group B), fosinopril reduced the events from 13.0% to 5.3%, a relative risk reduction of 59.2%.
Conclusion Fosinopril reduces cardiovascular events to a greater extent in patients with albumin excretion above 50 mg/24h. Background ACE-inhibitors and HMG-CoA reductase inhibitors have shown to reduce the progression of intima-media-thickness (IMT) in patient populations with hypertension or hypercholesterolemia. PREVEND-IT investigated the effect of fosinopril and pravastatin on IMT in non-hypertensive, non-hypercholesterolemic microalbuminuric subjects.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention
Trial is a double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864). Subjects were randomized to pravastatin 40 mg or matching placebo and to fosinopril 20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-300mg/24h), no hypertension (<160/100mmHg) and no hypercholesterolemia (<308 mg/ dl). Microalbuminuria was measured in 2x24 hour urine collection. The IMT was measured at the posterior wall of the left common carotid artery using radio frequency signal analysis obtained by M-mode ultra-sonography. Results Mean age was 50.8 ± 11.4 years and 65% was male. The table below shows the median IMT at baseline and after 4 years of follow-up divided by the different strategies. These median IMT values are within the range of normal values found in our laboratory. Conclusion Neither fosinopril and pravastatin showed an effect on the carotid IMT after 4 years of follow-up. The normal IMT values found in this population suggests that microalbuminuria is an early risk indicator already present before detectable vascular changes.
5:00 p.m.
825-5 Long-Term Bosentan Improves the Quality of Life of Patients With Pulmonary Arterial Hypertension
Adaani Frost, The BREATHE-1 Study Group, Baylor College of Medicine and the Methodist Hospital, Houston, TX Background: Bosentan is an oral endothelin receptor antagonist that improves hemodynamics and delays the time to clinical worsening in patients with pulmonary arterial hypertension (PAH). In the BREATHE-1 study, the effect of long-term bosentan treatment on the well being of PAH patients was investigated. Methods: 213 patients with PAH (primary or associated with scleroderma) in WHO functional class III or IV were enrolled in a double-blind, placebo-controlled study for 16 weeks (2:1 bosentan:placebo). Of these patients, 48 (35 bosentan; 13 placebo) continued double-blind study medication for up to 28 weeks (median exposure 26.9 weeks for bosentan, 26.3 weeks for placebo). Patients received bosentan (62.5 mg bid for 4 weeks then 125 or 250 mg bid) or placebo. Efficacy endpoints included the 6-minute walk distance, Borg dyspnea index and WHO functional class.
Results: Bosentan significantly improved the 6-minute-walk distance at Week 16 (+36 ± 6 m, mean ± sem) compared to placebo (-8 ± 12 m), (p < 0.001, n = 213), and the improvement was maintained for up to 28 weeks (bosentan: +43 ± 14 m; placebo +6 ± 21 m, n = 48). In parallel, the Borg dyspnea index was decreased with bosentan and increased with placebo resulting in a mean treatment effect of -0.6 (CI: Vascular Disease, Hypertension, and Prevention (23%). Over the two study periods, a smaller proportion of patients on bosentan than on placebo required epoprostenol therapy (2.8% versus 4.3%), additional therapy for PAH (28.6% versus 38.5%), or hospitalization (4.2% versus 13.0% for PAH-related and 16.0% versus 23.2% for all causes of hospitalization).
Conclusion:
The benefit achieved in exercise capacity, dyspnea, and reduced need for additional therapy or hospitalization demonstrated in the initial 16-week BREATHE-1 study appears to be sustained when patients are followed for 28 weeks. Purpose: Folic acid has favourable effects on vascular endothelium and lowers plasma homocysteine levels. In addition, homocysteine appears to be an independent risk factor for atherosclerotic disease. However, the value of folic acid in secondary prevention had seldom been tested. Two yr folic acid treatment in the randomized GOES study showed no reduction in clinical endpoints despite a 18% homocysteine reduction in patients on folic acid. Suggested was that the follow up could have been too short, therefore the study was extended with another 18 months Tx. Here we report results of the extended Goes trial, an open-label trial with folic acid 0.5 mg per day in a patient population with stable coronary artery disease (CAD). Methods: 593 Patients were included in this study; 300 were randomized to folic acid and 293 served as controls. Mean follow-up time was 42 months. At baseline all patients had been on statin therapy for a mean of 3.2 years. Results: In patients treated with folic acid plasma homocysteine levels decreased with 18% from 12.0 ± 4.8 to 9.4 ± 3.5 µmol/L, while these levels remained unaffected in the control group (p <0.001 between groups). The primary endpoint (all-cause mortality and a composite of vascular events) was encountered in 75 (25.0%) patients in the folic acid group and in 75 (25.6%) patients in the control group (RR 0.98; p=NS). Also in the quartile of patients with the highest baseline homocysteine levels (>13.7 micromol/L) no salutary effects of folic acid Tx could be demonstrated. In a multifactorial survival model with adjustments for clinical factors the most predictive laboratory parameters were, in order of significance, levels of creatinine clearance, and homocysteine. Conclusions: Within 3.5 years folic acid does not seem to reduce clinical endpoints in patients with stable CAD while on statin treatment. Homocysteine might therefore merely be a marker of disease than a causal risk factor. Thus, until more trials will become available, low dose folic acid supplementation should be treated with reservation. Methods: Intracoronary ultrasound automated pull-backs were recorded on S-VHS tape both before and after twelve months of lipid-lowering therapy in a target coronary artery in 18 subjects with known coronary artery disease. The pullbacks were digitized and calibrated, and identical segments with plaque in the target artery were identified on the preand post-therapy images. The lumen and adventitia-media borders were manually traced on all images in the segment that allowed image interpretation, with the longitudinal position noted. The plaque and adventitial volumes were calculated by a numerical integration of the area over the longitudinal length. The mean plaque adventitial, and lumen areas in sq. mm were calculated based on plaque and adventitial volume and segment length.
Results:
The change in mean lumen area was poorly correlated with the change in mean plaque area (R = 0.256, p = 0.306). Lumen area change was strongly correlated with adventitial area change (R = 0.903, p <0.001, see figure below) The relationship was Change in mean lumen area = 0.712 x Change in mean adventitial area + 0.347 mm2.
Conclusions:
The changes in lumen area after one year of lipid-lowering therapy are better correlated with adventitial change than with plaque change, indicating that arterial remodeling is an important determinant of lumen change.
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831-3 Circulating Endothelial Progenitor Cells Predict Coronary Artery Disease Severity

